Pursuant to Regulation 30 of SEBI LODR, Wanbury has informed that company’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. The inspection was conducted by two senior inspectors from South Korea’s MFDS, a leading international pharmaceutical regulatory authority, covering the facility’s compliance with applicable Good Manufacturing Practices (cGMP) standards. This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the Company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations. These consecutive achievements reflect Wanbury Limited’s strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations.
The above information is a part of company’s filings submitted to BSE.